Altimmune completes dosing in the Phase 2 MOMENTUM trialAltimmune has completed dosing (last subject last dose) in its 48-week Phase 2 MOMENTUM trial evaluating the efficacy and safety of...
Altimmune begins MOMENTUM obesity trial for PemvidutideAltimmune has enrolled the first subject in the 48-week Phase 2 MOMENTUM trial evaluating the safety and efficacy of pemvidutide in...
LSG and RYGB-induced upregulation of apoA-IV is beneficial for insulin secretion and energy expenditure2 days ago
Tirzepatide reduced sleep apnoea severity by up to nearly two-thirds in adults living with OSA and obesity2 days ago